Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence.
Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence.
复制标题
DOI：
10.1038/s41467-022-35454-4
复制
发表时间：
2022-12-15
影响因子：
16.6
通讯作者：
Peters, James E.
中科院分区：
文献类型：
--
作者：
Gisby, Jack S.;Buang, Norzawani B.;Papadaki, Artemis;Clarke, Candice L.;Malik, Talat H.;Medjeral-Thomas, Nicholas;Pinheiro, Damiola;Mortimer, Paige M.;Lewis, Shanice;Sandhu, Eleanor;McAdoo, Stephen P.;Prendecki, Maria F.;Willicombe, Michelle;Pickering, Matthew C.;Botto, Marina;Thomas, David C.;Peters, James E.
终末期肾病（ESKD）患者是严重COVID-19的高风险人群。在这里，我们对ESKD血液透析患者的COVID-19进行纵向血液采样，在感染前、感染期间和临床恢复后连续采集样本。利用血浆蛋白质组学、RNA测序和免疫细胞流式细胞术，我们确定了COVID-19严重程度的转录组学和蛋白质组学特征，并在严重疾病患者中发现了不同的时间分子谱。监督学习揭示了血浆蛋白质组是比PBMC转录组更好的临床严重性的上级指标。我们发现，血浆LRRC 15（SARS-CoV-2的辅助受体）的下降轨迹与更严重的临床病程相关。我们观察到，在急性感染后两个月，患者仍然表现出与血管，血小板和凝血途径相关的基因表达失调，包括PF 4（血小板因子4），这可能解释了COVID-19后血栓形成风险的延长。终末期肾脏疾病导致严重COVID-19感染的风险很高。作者使用高危人群（患有COVID-19的终末期肾病患者），使用免疫细胞的RNA测序和血浆蛋白质组学分析来研究宿主对病毒感染的反应。
Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. Here, we perform longitudinal blood sampling of ESKD haemodialysis patients with COVID-19, collecting samples pre-infection, serially during infection, and after clinical recovery. Using plasma proteomics, and RNA-sequencing and flow cytometry of immune cells, we identify transcriptomic and proteomic signatures of COVID-19 severity, and find distinct temporal molecular profiles in patients with severe disease. Supervised learning reveals that the plasma proteome is a superior indicator of clinical severity than the PBMC transcriptome. We show that a decreasing trajectory of plasma LRRC15, a proposed co-receptor for SARS-CoV-2, is associated with a more severe clinical course. We observe that two months after the acute infection, patients still display dysregulated gene expression related to vascular, platelet and coagulation pathways, including PF4 (platelet factor 4), which may explain the prolonged thrombotic risk following COVID-19. End-stage kidney disease confers a high risk for severe COVID-19 infection. Using an at-risk group (end-stage kidney disease patients with COVID-19), authors using RNA-sequencing of immune cells and plasma proteomic profiling to investigate the host response to viral infection.
登录
查看更多内容
影响因子：
16.6
作者：
Buang N;Tapeng L;Gray V;Sardini A;Whilding C;Lightstone L;Cairns TD;Pickering MC;Behmoaras J;Ling GS;Botto M
通讯作者：
Botto M
DOI：
10.1093/bioinformatics/btu638
发表时间：
2015-01-15
期刊：
Bioinformatics (Oxford, England)
影响因子：
--
作者：
Anders S;Pyl PT;Huber W
通讯作者：
Huber W
影响因子：
64.5
作者：
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk;COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium
通讯作者：
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
DOI：
10.1056/nejmoa2104840
发表时间：
2021-06-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者：
Eichinger S